Business Wire

BIOCORP and ROCHE DIABETES CARE FRANCE Launch Mallya, an Innovative Medical Device to Better the Daily Life of Patients With Diabetes

Share

Regulatory News:

BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME) , a French company specialized in the design, development and manufacturing of innovative medical devices, and Roche Diabetes Care France, a reference company in the support of patients with diabetes, announce the launch in France of Mallya, a medical device available in pharmacies. Developed by BIOCORP, this smart insulin pen device collects and transfers insulin data with near 100% accuracy2. Rechargeable via its USB port, Mallya is compatible with most disposable insulin pens1. This innovation aims to simplify the daily life of patients with diabetes undergoing insulin therapy, and could help avoid errors or oversights.

Healthcare companies BIOCORP and Roche Diabetes Care France are finalizing their collaboration - announced last June - with the distribution of Mallya smart devices for insulin injection pens since the beginning of April. Manufactured in Clermont-Ferrand (France), this innovation for patients taking insulin is the first in its category to receive the CE-mark (medical device).

Reusable and compatible with 91%1 of disposable insulin pens, Mallya automatically collects insulin data (dose, date, time) and transfers it to the Gluci-Chek application developed by Roche Diabetes Care France, ensuring qualified information on which the patient can rely and the physician can then make decisions3. With integration into the Roche Diabetes Care France digital ecosystem, patients benefit from solutions that lighten the mental burden of their disease, in a context where more than 750,000 people4 are treated with insulin injections in France (excluding insulin pumps).

“The commercial launch of Mallya represents an important milestone for BIOCORP. We are really proud to be leading it with Roche Diabetes Care France. Its leading position, its vast distribution network in pharmacies and the connection of our innovative device to its Gluci-Chek solution present undeniable benefits for all healthcare professionals but also and above all for diabetic patients looking for a better quality of life, a better comfort in the management and daily follow-up of their disease", said Eric Dessertenne, CEO of BIOCORP.

"For more than 40 years, we have been helping people with diabetes think less about the day-to-day management of their disease. We are committed to the autonomy and quality of life of patients with diabetes, empowering them to understand and act on their condition. This is precisely what Mallya allows, when integrated with our digital ecosystem for patients and healthcare professionals. We are currently the only company to offer a quality solution based on a CE marked medical device", added Frédéric Jacquey, President of Roche Diabetes Care France.

An innovation to improve the daily life and monitoring of diabetic patients on insulin

After the creation of insulin for therapeutic purposes 100 years ago, innovation continues in the field of diabetes, with the same ambition: to enable more and more patients to live better with their diabetes on a daily basis, a strong challenge for patients treated with insulin. To this end, Mallya collects and transfers insulin data in real time5 to their smartphone.

Once the device is installed, the patient selects and injects his or her insulin units as usual, with data transfer (date, time, selected dose) being done automatically. While 37%6 of patients with diabetes felt more anxious about their condition during the first Covid19 confinement, the simple and accurate2 Mallya device makes it easier for them to follow the evolution of their disease. It could thus contribute to more serenity, more security and less error or forgetfulness in taking their treatment.

Shared with healthcare professionals3 through the dedicated Roche Diabetes Care Platform, accurate and comprehensive insulin data2 allows them to monitor - face-to-face or remotely - the progress of their patients' disease, refine their interpretation and help adjust treatment decisions.

A device integrated into a global solution to facilitate diabetes management

The device enhances Roche Diabetes Care France's digital ecosystem for integrated personalized diabetes management. This solution was previously based on three elements: connected blood glucose meters (Accu-Chek® Mobile, Accu-Chek® Guide), the Gluci-Chek application and the Roche Diabetes Care platform dedicated to healthcare professionals. Mallya is adding insulin data for more comprehensive patient monitoring.

Used regularly by more than 60,000 diabetic patients in France, this smartphone application combines three major functionalities for personalized diabetes management: a carbohydrate calculation tool with a visualization of the portions on the plate, a self-monitoring of blood glucose diary and a graphic visualization of glycemic results.

Once Mallya is connected to Gluci-Chek, the patient no longer has to manually report his or her insulin doses, as the data is automatically displayed in the patient's blood glucose logbook, for any compatible insulin pen1. In a context where French people are confined again and where 58%3 of patients with diabetes did not feel they had received any particular help during their first confinement, this connected device can provide real close monitoring.

ABOUT ROCHE DIABETES CARE FRANCE

Roche Diabetes Care is a healthcare company specializing in diabetes. For more than 40 years, it has been pioneering solutions to meet the needs of patients and healthcare professionals: medical devices (blood glucose meters, auto-pickers, insulin pumps), digital solutions (applications, platform for sharing blood glucose data between patients and healthcare professionals) and services (information and therapeutic education support). Through the implementation of a global solution connecting medical devices and digital solutions, Roche Diabetes Care is paving the way for integrated Personalized Diabetes Management (iPDM), with the aim of facilitating and optimizing the management and monitoring of this complex disease.

Roche Diabetes Care France is a subsidiary of the Roche Group in France, alongside Roche SAS France and Roche Diagnostics France. For more information, please visit www.roche.fr.

ABOUT BIOCORP

Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 70 employees. BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR). For more information, please visit www.biocorpsys.com.

1 The Mallya medical device is compatible with Solostar pens (ref. 9828648001), FlexPen pens (ref. 9832360001) and KwikPen pens (ref. 9827587001) with the exception of Junior KwikPen pens as of January 1, 2021. Calculation of market share for disposable insulin pens from Caisse Nationale d'Assurance Maladie. Open Medic 2019 database.

299% according to Mallya IFU version 6. Caution: some external factors may affect the accuracy of dose measurement or data transfer.

3If the patient decides to share his/her data.

4Source: IQVIA - LTD : Analysis of BGMin real life – Meters and strips markets - CMA February 2020 - Patients and volume.

5 As soon as Bluetooth is activated.

6 Online study conducted by CSA Research for Roche Diabetes Care France from May 18th to 27th, 2020, with 504 diabetic patients (101 type1 diabetic patients and 403 type2 diabetic patients)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

BIOCORP
Jacques Gardette
Chairman of the Board
investisseurs@biocorp.fr

Éric Dessertenne
Chief Executive Officer

Sylvaine Dessard
Marketing & Communication Director
rp@biocorp.fr
+ 33 (0)6 88 69 72 85

ULYSSE COMMUNICATION
Bruno Arabian
barabian@ulysse-communication.com
+33 (0)6 87 88 46 26

Nicolas Daniels
ndaniels@ulysse-communication.com
+33 (0)6 63 66 59 22

ROCHE DIABETES CARE FRANCE
Myriam Hamza
rochediabpresse@havas.com
+33 (0)6 45 87 46 51

Nathalie Neyroz
nathalie.neyroz@roche.com
+33 (0)7 78 38 09 12

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Raven Industries Launches the OMNi Brand12.5.2021 15:15:00 CEST | Press release

Raven Industries, Inc.(the Company; NASDAQ:RAVN) a leader in agriculture technology, announced today the launch of its new product brand and autonomous growth platform, OMNi. This new product brand highlights Raven’s advancements in autonomous solutions for agriculture with a strategic offering of two integrated products: OMNiDRIVE™ and OMNiPOWER™. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210512005126/en/ The OMNi name (meaning "all") will take center stage within Raven. “Empowering ‘all’ is exactly what OMNiPOWER™ and OMNiDRIVE™ bring to the agriculture industry. OMNi enables holistic, hands-free precision; it gives the farmer total control of their time and maximizes operational productivity and efficiency,” said Nick Langerock, Director of Strategic Marketing for Raven. “As we bring OMNi to market, we want farmers to understand that some of their pain points are now more manageable through autonomous solutions. OMNi

SentinelOne Receives Highest Score for the Type A Use Case (“Lean Forward” Organizations) in the Gartner 2021 Critical Capabilities for Endpoint Protection Platforms12.5.2021 15:00:00 CEST | Press release

SentinelOne, the autonomous cybersecurity platform company, today announced that Gartner has positioned SentinelOne with the highest score in use case Type A in Gartner’s 2021 Critical Capabilities for Endpoint Protection Platforms report1. SentinelOne received the highest score for all three customer types out of 19 vendors. Gartner says, “Type A organizations, also referred to as 'lean forward' organizations, adopt new technologies very early in the adoption cycle.” “We believe receiving the highest product score among early technology adopters in the 2021 Critical Capabilities for Endpoint Protection Platforms validates our commitment to disrupt and broaden the endpoint space,” said Raj Rajamani, Chief Product Officer, SentinelOne. “These organizations tend to focus on innovative solutions that address their business, technology and security needs. Receiving the highest score for 'lean forward' companies highlights our ability to take cybersecurity defenses to new levels of speed, e

New CloudBlue Revenue Management Solution Solves for Recurring Billing Reconciliation12.5.2021 15:00:00 CEST | Press release

CloudBlue, a leading cloud ecosystem technology company, announced today the launch of CloudBlue Rev, a solution that enables partners to ‘rev’ up their channel revenue management. CloudBlue Rev simplifies and streamlines channel revenue management to enhance efficiency, save time and increase profitability. Available now in the United Kingdom with planned rollouts across the world, learn more here. The new solution is based on the recently acquired HarmonyPSA architecture and is the latest addition to CloudBlue’s rapidly expanding portfolio of technologies and services for the channel. CloudBlue Rev helps channel reseller partners regain valuable time as they transition to an everything-as-a-service business by automating quoting, billing and reconciliation. By streamlining these processes into a single platform, resellers will now be able to automate profit tracking across sales motions with integrated discounting and markup, as well as quickly set margins and gain insight into contr

Hiro Capital Leads $6.4m Investment in Game Innovators Twin Suns Corp and FRVR12.5.2021 15:00:00 CEST | Press release

Twin Suns Corp and FRVR will use Hiro’s $6.4m of investment to expand development and to accelerate growth. Twin Suns Corp is a new AAA-game studio, founded by >20-year industry veterans - Tim Longo Jr. (Star Wars: Republic Commando, Halo, Tomb Raider), Forest Swartout Large (Hitman and Tomb Raider), and Jeff Morris (Gears of War and Unreal Tournament). Twin Suns Corp is building a next-gen AAA cross-platform title that will launch an exciting new IP franchise; with additional team members that have worked on Star Wars, Tomb Raider, Hitman, Halo, Elder Scrolls, Fallout, Gears of War, Unreal Tournament and Avengers. FRVR is an instant games ecosystem platform powering frictionless game play on any device, founded by Chris Benjaminsen (Yahoo, PlayerScale) and Brian Meidell (Cape, GameAnalytics) With more than 1bn players, FRVR has partnerships that puts their tech and games onto billions of devices. Twin Suns Corp and FRVR join other creator-founded Games teams Polyarc, Snowprint, Lightf

Nuclera Acquires E Ink Digital Microfluidics Unit12.5.2021 14:53:00 CEST | Press release

Nuclera, a fast-growing biotech company developing enzymatic protein and gene synthesis technologies, and E Ink, the leading innovator of electronic ink technology, are pleased to announce the acquisition of E Ink’s digital microfluidics unit into the newly formed US subsidiary of Nuclera. Combining the technologies of the two companies will enable the delivery of a revolutionary desktop protein and gene “bioprinter” with breakthrough speed and convenience for researchers in human health, agriculture, and other markets of global importance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210512005575/en/ Nuclera desktop bioprinter powered by digital microfluidic technology. (Photo: Business Wire) Nuclera has been working in a strategic partnership with E Ink since 2018 to deploy Nuclera’s proprietary biopolymer synthesis technologies on E Ink’s digital microfluidic devices. Instead of the physical channels found in convention

Esri Partners with International Community to Scale GIS Technology for Sustainable Development12.5.2021 14:00:00 CEST | Press release

Esri, the global leader in location intelligence, today announced its contribution to an open, community-driven partnership working to accelerate the achievement of the United Nations Sustainable Development Goals (SDGs). Governments, international organizations, foundations, universities, and civil society groups are joining the initiative to offer resources and expertise, including capacity-building efforts, that will enable virtual Centers of Excellence for Geospatial Information to provide greater access to SDG data for nations in need. “This collaboration will bring the innovations of geospatial information science to a wider public,” said Jeffrey Sachs, University Professor and Director of the Center for Sustainable Development, Columbia University, President of the UN Sustainable Development Solutions Network, SDG Advocate under UN Secretary-General António Guterres, and Chair of the Lancet COVID-19 Commission. “The virtual centers will empower communities around the world with

Thales Expands Its Access Management Capabilities to Offer a Unified Authentication Platform12.5.2021 14:00:00 CEST | Press release

Thales has announced an expansion of its SafeNet Trusted Access solution, offering customers full access management protection across all applications or services in any IT environment. Whether it’s in the cloud, on-premise or through an API, Thales’ customers will now be able to benefit from modern authentication capabilities to ensure applications can only be accessed by those authorised to do so. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210512005414/en/ ©Thales On-Premises lingers as API and Cloud adoption rises With the growing use of cloud computing, access management has broadened its scope to address authorisation and authentication beyond human identities. Businesses are increasingly relying on APIs to integrate services and utilise the exchange of data. However, increased reliance on unvalidated APIs can leave businesses vulnerable to an unauthorised or compromised API accessing their applications and services